JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 58)
eröffnet am 22.11.07 16:46:06 von
neuester Beitrag 16.05.24 14:38:19 von
neuester Beitrag 16.05.24 14:38:19 von
Beiträge: 613
ID: 1.135.563
ID: 1.135.563
Aufrufe heute: 14
Gesamt: 130.573
Gesamt: 130.573
Aktive User: 0
ISIN: US4781601046 · WKN: 853260 · Symbol: JNJ
140,18
EUR
-1,46 %
-2,08 EUR
Letzter Kurs 20:02:02 Tradegate
Neuigkeiten
| Johnson & Johnson Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
17:50 Uhr · wO Newsflash |
16.05.24 · Business Wire (engl.)  |
08.05.24 · Business Wire (engl.) |
Werte aus der Branche Konsum
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5900 | +18,00 | |
| 15,800 | +16,18 | |
| 1,6500 | +12,24 | |
| 13,850 | +11,16 | |
| 1,6100 | +9,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7000 | -6,90 | |
| 2,3900 | -8,08 | |
| 11,000 | -8,10 | |
| 3,7200 | -11,22 | |
| 1,7342 | -14,11 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 33.736.208 von spaceistheplace am 27.03.08 08:48:20Lieber space,
habe durch Zufall Deinen thread gefunden.
Langeweile macht sich auch hier - wie bei WMT - bezahlt:
Ich erwarte neue highs, Quartalsergebnis heute über dem Konsens, sogar über der höchsten Einzelschätzung.
Näheres kann jeder selber nachlesen.
habe durch Zufall Deinen thread gefunden.
Langeweile macht sich auch hier - wie bei WMT - bezahlt:
Ich erwarte neue highs, Quartalsergebnis heute über dem Konsens, sogar über der höchsten Einzelschätzung.
Näheres kann jeder selber nachlesen.
San Diego, California (ots/PRNewswire) -
- Newly Established Organization Presents Data on Advancing
Compounds at AACR -
Ortho Biotech Oncology Research & Development (ORD), a unit of
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., will
announce results from studies of three innovative compounds--Hdm2,
c-Met, and HDAC inhibitors --here at the American Association for
Cancer Research (AACR) 2008 Annual Meeting.
ORD is a new research and development organization that unites
the biotechnology and pharmaceutical oncology efforts of several
Johnson & Johnson companies with the goal of transforming cancer into
a chronic or curable disease, said William Hait, M.D., Senior Vice
President and Worldwide Head of Ortho Biotech Oncology Research &
Development. The new organization harnesses broad,
multi-disciplinary capabilities and expertise in order to prioritize
existing and emerging opportunities, align cancer treatment with
modern cancer biology and improve patients' lives.
ORD's scientific approach to cancer examines the cancer cell and
the surrounding tissue, or microenvironment. Previously, researchers
often studied cancer as collections of malignant cells growing in
isolation, but now understand cancer cells depend on interactions
with the surrounding tissue to survive, grow and metastasize. ORD
seeks to identify compounds which can inhibit or block the
interaction cancer cells have with the surrounding tissues, which
compromises the cancer's ability to survive.
The organization will combine the microenvironment disruptive
agents (MDAs) resulting from this approach with classic treatments
that directly target cancer cells. MDAs represent one of the most
promising areas of drug discovery, and ORD has a pipeline of several
investigational MDAs, including some of which are first-in-class and
first-in-clinic.
Pre-clinical data presented at this year's AACR meeting
demonstrate evidence of broad-spectrum, anti-tumor activity for three
new compounds. These compounds selectively target specific pathways
and influence the interaction between cancer cells and the
microenvironment to induce cancer cell death. The presentations
include:
- JNJ-26854165, a first-in-class, first-in-clinic Hdm2 inhibitor
which induces apoptosis (programmed cell death) in a number of cancer
cell lines, and restores function of the p53 tumor suppressor protein
through a novel mechanism of action; the compound is in phase I
studies for non-small cell lung cancer and prostate cancer. (Oral
abstract #1592)
- JNJ-26481585, a novel, second-generation pan-Histone
Deacetylase (HDAC) inhibitor with anti-tumor activity against solid
and hematological malignancies, which interferes with expression of
genes that control cancer cell proliferation, angiogenesis and
metastasis; phase I trials are ongoing. (Oral abstract #2444)
- JNJ-38877605, a small molecule that selectively and potently
inhibits the c-Met receptor tyrosine kinase (c-Met RTK) pathway that
regulates inhibition of signaling from the microenvironment to block
cancer cell development and metastasis; based on promising
pre-clinical properties and clean toxicity profile of JNJ-38877605,
ORD has advanced this potent and uniquely selective c-Met inhibitor
into clinical evaluation in multiple metastasized malignancies.
(Poster abstract #4837)
These new agents are just a few of the novel compounds from our
pipeline that we hope may lead to the control of cancer, Dr. Hait
said. The scientific community is attempting to identify all the
genetic abnormalities within cancer cells; this has yielded a finite
number of treatment opportunities. The scientific approach of ORD has
the potential to generate new opportunities to improve cancer care.
About Our Compound Targets
Human Double Minute 2 (Hdm2)
The Hdm2 oncogene is activated in cancers through various
mechanisms, including gene amplification and deletion of upstream
tumor suppressors. Hdm2 over-expression induces tumor formation, and
Hdm2 levels correlate with sporadic tumor incidence in humans(i).
Hdm2 promotes tumor cell proliferation by associating with cell cycle
regulatory proteins, modulating their activity and stability. Key
examples include p53, p73, E2F1 and HIF1a(ii),(iii). This positions
the Hdm2 protein as an attractive target for the development of
anti-cancer agents.
Histone Deacetylase (HDAC)
DNA in chromatin is wound around proteins called histones. HDACs
are a family of enzymes that influence gene expression through
selective regulation of chromatin structure. Inappropriate gene
expressions, due to changes in chromatin structure, are a hallmark of
cancer. HDAC inhibitors aim to normalize chromatin structure, thereby
restoring the activity of genes which inhibit proliferation,
angiogenesis and metastasis(iv).
c-Met Receptor Tyrosine Kinase (c-Met RTK)
Receptor tyrosine kinases (RTKs) are cell surface receptors that
regulate many key processes including invasive growth and cell
survival. The c-Met RTK pathway has been shown to be specifically
important in regulation of cell migration and invasion, cell
proliferation, survival and angiogenesis. Deregulation of c-Met RTKs
has been implicated in the development and progression of numerous
human cancers. The c-Met RTK inhibitors prevent receptor activation
and thus inhibit tumor cell development and
metastasis(v),(vi),(vii),(viii).
About ORD
Ortho Biotech Oncology Research & Development (ORD) is a new
research and development organization dedicated to oncology,
hematology and supportive care. ORD partners closely with Ortho
Biotech Products, L.P. and Janssen-Cilag companies worldwide to bring
oncology treatments and supportive medicines to patients around the
world. ORD is headquartered in Raritan, N.J., and has facilities
throughout Europe and the United States.
(This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
the Company's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health
care reforms and governmental laws and regulations; and trends toward
health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year
ended December 30, 2007. Copies of this Form 10-K, as well as
subsequent filings, are available online at http://www.sec.gov,
http://www.jnj.com or on request from Johnson & Johnson. Johnson &
Johnson does not undertake to update any forward-looking statements
as a result of new information or future events or developments.)
(i) Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC,
Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ,
Strong LC, Lozano G, Levine AJ. A Single Nucleotide Polymorphism in
the MDM2 Promoter Attenuates the p53 Tumour Suppressor Pathway and
Accelerates Tumour Formation in Humans. Cell; 2004; 119: 591-602.
(ii) Levine, A J; Hu, W; Feng, Z. The P53 pathway: what questions
remain to be explored? Cell Death and Differentiation; 2006, 13(6),
1027-1036.
(iii) Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets
in anticancer therapy. International Journal of Biochemistry & Cell
Biology; 2007, 39(7-8):1476-82.
(iv) Johnstone, RW. Histone deacetylase inhibitors: novel drugs
for the treatment of cancer. Nature Reviews Drug Discovery; 2002, 1,
287 - 299.
(v) Lesko, E and Majka, M. The biological role of HGF-MET axis in
tumor growth and developmentof metastasis. Fron Biooscie; 2008, 13:
1271-80.
(vi) Sattler, M and Salgia R. c-Met and hepatocyte growth factor;
potential as novel targets in cancer theray. Curr Oncol Rep; 2007, 9
(2) 102-8.
(vii) Boccaccio C, and Comoglio, PM. Invasive growth; a MET
driven genetic programme for cancer and stem cells. Nat Rev Cancer;
2007, 6(8) 637-45.
(viii) Peruzzi, B and Bottaro, DP. Targeting the c-Met signaling
pathway in cancer. Clin Cancer Res; 2006, 12(12) 3657-60.
ots Originaltext: Ortho Biotech
Im Internet recherchierbar: http://www.presseportal.de
Contact:
Media Contact: William Foster, +1-908-541-4057, Investor Relations:
Tina Pinto, +1-732-524-2034
Quelle: http://www.worldofinvestment.com/news/intern//50240/
- Newly Established Organization Presents Data on Advancing
Compounds at AACR -
Ortho Biotech Oncology Research & Development (ORD), a unit of
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., will
announce results from studies of three innovative compounds--Hdm2,
c-Met, and HDAC inhibitors --here at the American Association for
Cancer Research (AACR) 2008 Annual Meeting.
ORD is a new research and development organization that unites
the biotechnology and pharmaceutical oncology efforts of several
Johnson & Johnson companies with the goal of transforming cancer into
a chronic or curable disease, said William Hait, M.D., Senior Vice
President and Worldwide Head of Ortho Biotech Oncology Research &
Development. The new organization harnesses broad,
multi-disciplinary capabilities and expertise in order to prioritize
existing and emerging opportunities, align cancer treatment with
modern cancer biology and improve patients' lives.
ORD's scientific approach to cancer examines the cancer cell and
the surrounding tissue, or microenvironment. Previously, researchers
often studied cancer as collections of malignant cells growing in
isolation, but now understand cancer cells depend on interactions
with the surrounding tissue to survive, grow and metastasize. ORD
seeks to identify compounds which can inhibit or block the
interaction cancer cells have with the surrounding tissues, which
compromises the cancer's ability to survive.
The organization will combine the microenvironment disruptive
agents (MDAs) resulting from this approach with classic treatments
that directly target cancer cells. MDAs represent one of the most
promising areas of drug discovery, and ORD has a pipeline of several
investigational MDAs, including some of which are first-in-class and
first-in-clinic.
Pre-clinical data presented at this year's AACR meeting
demonstrate evidence of broad-spectrum, anti-tumor activity for three
new compounds. These compounds selectively target specific pathways
and influence the interaction between cancer cells and the
microenvironment to induce cancer cell death. The presentations
include:
- JNJ-26854165, a first-in-class, first-in-clinic Hdm2 inhibitor
which induces apoptosis (programmed cell death) in a number of cancer
cell lines, and restores function of the p53 tumor suppressor protein
through a novel mechanism of action; the compound is in phase I
studies for non-small cell lung cancer and prostate cancer. (Oral
abstract #1592)
- JNJ-26481585, a novel, second-generation pan-Histone
Deacetylase (HDAC) inhibitor with anti-tumor activity against solid
and hematological malignancies, which interferes with expression of
genes that control cancer cell proliferation, angiogenesis and
metastasis; phase I trials are ongoing. (Oral abstract #2444)
- JNJ-38877605, a small molecule that selectively and potently
inhibits the c-Met receptor tyrosine kinase (c-Met RTK) pathway that
regulates inhibition of signaling from the microenvironment to block
cancer cell development and metastasis; based on promising
pre-clinical properties and clean toxicity profile of JNJ-38877605,
ORD has advanced this potent and uniquely selective c-Met inhibitor
into clinical evaluation in multiple metastasized malignancies.
(Poster abstract #4837)
These new agents are just a few of the novel compounds from our
pipeline that we hope may lead to the control of cancer, Dr. Hait
said. The scientific community is attempting to identify all the
genetic abnormalities within cancer cells; this has yielded a finite
number of treatment opportunities. The scientific approach of ORD has
the potential to generate new opportunities to improve cancer care.
About Our Compound Targets
Human Double Minute 2 (Hdm2)
The Hdm2 oncogene is activated in cancers through various
mechanisms, including gene amplification and deletion of upstream
tumor suppressors. Hdm2 over-expression induces tumor formation, and
Hdm2 levels correlate with sporadic tumor incidence in humans(i).
Hdm2 promotes tumor cell proliferation by associating with cell cycle
regulatory proteins, modulating their activity and stability. Key
examples include p53, p73, E2F1 and HIF1a(ii),(iii). This positions
the Hdm2 protein as an attractive target for the development of
anti-cancer agents.
Histone Deacetylase (HDAC)
DNA in chromatin is wound around proteins called histones. HDACs
are a family of enzymes that influence gene expression through
selective regulation of chromatin structure. Inappropriate gene
expressions, due to changes in chromatin structure, are a hallmark of
cancer. HDAC inhibitors aim to normalize chromatin structure, thereby
restoring the activity of genes which inhibit proliferation,
angiogenesis and metastasis(iv).
c-Met Receptor Tyrosine Kinase (c-Met RTK)
Receptor tyrosine kinases (RTKs) are cell surface receptors that
regulate many key processes including invasive growth and cell
survival. The c-Met RTK pathway has been shown to be specifically
important in regulation of cell migration and invasion, cell
proliferation, survival and angiogenesis. Deregulation of c-Met RTKs
has been implicated in the development and progression of numerous
human cancers. The c-Met RTK inhibitors prevent receptor activation
and thus inhibit tumor cell development and
metastasis(v),(vi),(vii),(viii).
About ORD
Ortho Biotech Oncology Research & Development (ORD) is a new
research and development organization dedicated to oncology,
hematology and supportive care. ORD partners closely with Ortho
Biotech Products, L.P. and Janssen-Cilag companies worldwide to bring
oncology treatments and supportive medicines to patients around the
world. ORD is headquartered in Raritan, N.J., and has facilities
throughout Europe and the United States.
(This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on current expectations of future events.
If underlying assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary materially from
the Company's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health
care reforms and governmental laws and regulations; and trends toward
health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year
ended December 30, 2007. Copies of this Form 10-K, as well as
subsequent filings, are available online at http://www.sec.gov,
http://www.jnj.com or on request from Johnson & Johnson. Johnson &
Johnson does not undertake to update any forward-looking statements
as a result of new information or future events or developments.)
(i) Bond GL, Hu WW, Bond EE, Robins H, Lutzker SG, Arva NC,
Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ,
Strong LC, Lozano G, Levine AJ. A Single Nucleotide Polymorphism in
the MDM2 Promoter Attenuates the p53 Tumour Suppressor Pathway and
Accelerates Tumour Formation in Humans. Cell; 2004; 119: 591-602.
(ii) Levine, A J; Hu, W; Feng, Z. The P53 pathway: what questions
remain to be explored? Cell Death and Differentiation; 2006, 13(6),
1027-1036.
(iii) Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets
in anticancer therapy. International Journal of Biochemistry & Cell
Biology; 2007, 39(7-8):1476-82.
(iv) Johnstone, RW. Histone deacetylase inhibitors: novel drugs
for the treatment of cancer. Nature Reviews Drug Discovery; 2002, 1,
287 - 299.
(v) Lesko, E and Majka, M. The biological role of HGF-MET axis in
tumor growth and developmentof metastasis. Fron Biooscie; 2008, 13:
1271-80.
(vi) Sattler, M and Salgia R. c-Met and hepatocyte growth factor;
potential as novel targets in cancer theray. Curr Oncol Rep; 2007, 9
(2) 102-8.
(vii) Boccaccio C, and Comoglio, PM. Invasive growth; a MET
driven genetic programme for cancer and stem cells. Nat Rev Cancer;
2007, 6(8) 637-45.
(viii) Peruzzi, B and Bottaro, DP. Targeting the c-Met signaling
pathway in cancer. Clin Cancer Res; 2006, 12(12) 3657-60.
ots Originaltext: Ortho Biotech
Im Internet recherchierbar: http://www.presseportal.de
Contact:
Media Contact: William Foster, +1-908-541-4057, Investor Relations:
Tina Pinto, +1-732-524-2034
Quelle: http://www.worldofinvestment.com/news/intern//50240/
Guten Morgen miteinander,
will mich mal melden, denn ich habe Euch was mitzuteilen:
Ich werde mich ab sofort aus WO und aus dem ganzen Börsengeschehen mehr oder minder zurückziehen. Ich habe mir das schon länger überlegt und bin jetzt über Ostern zu diesem Schluss gekommen.
Ich habe gestern fast komplett meinen Aktienbestand verkloppt. Ich habe mit meiner Bank, bei der ich einen Kredit über unser Haus laufen habe, ein große Sondertilgung vereinbart und werde diese in diesen Tagen durchführen. Da fließt das Geld hinein. Lieber meinen Kredit tilgen bzw. abbezahlen als auf im Endeffekt höhere Renditen am Markt spekulieren. Das kann böse in die Hose gehen bzw. ich denke, das eben die Renditen an den Märkten in den nächsten jahren nicht zum Himmel wachsen. Nummer Sicher, fertig...
Ein sehr kleiner Rest ist noch nicht über die Spekufrist (sind aber eh keine großen Gewinne drauf), warte diese aber ab. Bis Ende des Jahres wird dann der Rest des Kredites abbezahlt.
Zudem bin ich auch zum Schluss gekommen, hier bei WO meine Aktivitäten einzustellen. Ich hatte ja schon öfters geschrieben, dass ich zu viel Zeit aufwende und dann doch immer wieder in die gleiche Schiene verfallen bin, einfach zu viel Zeit dafür aufzuwenden, oft auch einfach zu verbissen war, was ich als nicht gut empfinde. Daher werde ich jetzt komplett aufhören und mich auch abmelden, sonst wird das wieder nix.
Also macht es gut, haltet den Thread auch ohne mich als Threadgrünmder warm…
Liebe Grüße an alle
space
will mich mal melden, denn ich habe Euch was mitzuteilen:
Ich werde mich ab sofort aus WO und aus dem ganzen Börsengeschehen mehr oder minder zurückziehen. Ich habe mir das schon länger überlegt und bin jetzt über Ostern zu diesem Schluss gekommen.
Ich habe gestern fast komplett meinen Aktienbestand verkloppt. Ich habe mit meiner Bank, bei der ich einen Kredit über unser Haus laufen habe, ein große Sondertilgung vereinbart und werde diese in diesen Tagen durchführen. Da fließt das Geld hinein. Lieber meinen Kredit tilgen bzw. abbezahlen als auf im Endeffekt höhere Renditen am Markt spekulieren. Das kann böse in die Hose gehen bzw. ich denke, das eben die Renditen an den Märkten in den nächsten jahren nicht zum Himmel wachsen. Nummer Sicher, fertig...
Ein sehr kleiner Rest ist noch nicht über die Spekufrist (sind aber eh keine großen Gewinne drauf), warte diese aber ab. Bis Ende des Jahres wird dann der Rest des Kredites abbezahlt.
Zudem bin ich auch zum Schluss gekommen, hier bei WO meine Aktivitäten einzustellen. Ich hatte ja schon öfters geschrieben, dass ich zu viel Zeit aufwende und dann doch immer wieder in die gleiche Schiene verfallen bin, einfach zu viel Zeit dafür aufzuwenden, oft auch einfach zu verbissen war, was ich als nicht gut empfinde. Daher werde ich jetzt komplett aufhören und mich auch abmelden, sonst wird das wieder nix.
Also macht es gut, haltet den Thread auch ohne mich als Threadgrünmder warm…
Liebe Grüße an alle
space
hört sich nicht so doll an:
Amgen, J&J Anemia Drugs Have Blood Clot, Death Risk - Study2-26-08 4:15 PM EST | E-mail Article | Print Article
WASHINGTON -(Dow Jones)- An analysis of about 50 studies involving Amgen Inc.'s (AMGN) and Johnson & Johnson (JNJ)'s anti-anemia drugs suggests the products are associated with an increased risk of death and blood clots.
The analysis, which is being published in this week's Journal of the American Medical Association, looked at 51 Phase III clinical studies involving Aranesp, Epogen and Procrit in patients with cancer and comes amid an ongoing safety review of the drugs by the U.S. Food and Drug Administration. Phase III studies are advanced clinical studies that are typically conducted to support FDA approval of products.
Previous studies have suggested the drugs increase the risk of blood clots and the drugs' labels already warn of that risk, while certain individual studies of the drugs in cancer patients have suggested the drugs might shorten overall survival.
Twice last year, the FDA updated the drugs' labels to warn of safety problems and the agency will be convening its outside advisory panel of cancer experts on March 13 to discuss two additional studies involving cancer patients that have come out since November. The agency has said it "may take" additional regulatory action involving the drugs but, for now, it has advised patients and doctors to discuss the benefits and risks of the products before deciding whether to use them.
The analysis, led by Charles L. Bennett, an oncologist and medical professor at Northwestern University, looked at 51 clinical trials with 13,611 patients to examine survival. Overall, the analysis showed patients being treated with the drugs had about a 10% higher risk of dying than patients not receiving the drugs, a finding Bennett said was "statistically significant." The risk of venous thromboembolism, or blood clots, was looked at in 38 studies that included 8,172 patients. Overall, those studies found an increased blood-clot risk of 57% among patients receiving the anti-anemia drugs.
"These risks have been previously defined," said Roger Perlmutter, Amgen's executive vice president of research and development. "There are benefits associated with use of these drugs and there are risks."
Amgen makes all three anti-anemia drugs, and Procrit is marketed by Ortho Biotech, a Johnson & Johnson unit, under a license agreement with Amgen. The drugs treat anemia by boosting the number of red-blood cells and are used to treat patients with kidney disease and certain cancer patients receiving chemotherapy. The drugs have been successful at helping patients avoid blood transfusions, which are necessary to boost red-blood cell levels that fall too low. The products fall into a class of drugs known as erythropoiesis-stimulating agents, or ESAs.
Bennett said more research is needed to look at the drugs' impact on tumors, noting that some studies have shown faster tumor growth, in order to figure out which patients should or shouldn't receive treatment with the drugs. Other research has suggested that the same mechanism the drugs use to boost red-blood cell counts could also fuel tumor growth.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com
(END) Dow Jones Newswires
02-26-081615ET
Copyright (c) 2008 Dow Jones & Company, Inc.
Amgen, J&J Anemia Drugs Have Blood Clot, Death Risk - Study2-26-08 4:15 PM EST | E-mail Article | Print Article
WASHINGTON -(Dow Jones)- An analysis of about 50 studies involving Amgen Inc.'s (AMGN) and Johnson & Johnson (JNJ)'s anti-anemia drugs suggests the products are associated with an increased risk of death and blood clots.
The analysis, which is being published in this week's Journal of the American Medical Association, looked at 51 Phase III clinical studies involving Aranesp, Epogen and Procrit in patients with cancer and comes amid an ongoing safety review of the drugs by the U.S. Food and Drug Administration. Phase III studies are advanced clinical studies that are typically conducted to support FDA approval of products.
Previous studies have suggested the drugs increase the risk of blood clots and the drugs' labels already warn of that risk, while certain individual studies of the drugs in cancer patients have suggested the drugs might shorten overall survival.
Twice last year, the FDA updated the drugs' labels to warn of safety problems and the agency will be convening its outside advisory panel of cancer experts on March 13 to discuss two additional studies involving cancer patients that have come out since November. The agency has said it "may take" additional regulatory action involving the drugs but, for now, it has advised patients and doctors to discuss the benefits and risks of the products before deciding whether to use them.
The analysis, led by Charles L. Bennett, an oncologist and medical professor at Northwestern University, looked at 51 clinical trials with 13,611 patients to examine survival. Overall, the analysis showed patients being treated with the drugs had about a 10% higher risk of dying than patients not receiving the drugs, a finding Bennett said was "statistically significant." The risk of venous thromboembolism, or blood clots, was looked at in 38 studies that included 8,172 patients. Overall, those studies found an increased blood-clot risk of 57% among patients receiving the anti-anemia drugs.
"These risks have been previously defined," said Roger Perlmutter, Amgen's executive vice president of research and development. "There are benefits associated with use of these drugs and there are risks."
Amgen makes all three anti-anemia drugs, and Procrit is marketed by Ortho Biotech, a Johnson & Johnson unit, under a license agreement with Amgen. The drugs treat anemia by boosting the number of red-blood cells and are used to treat patients with kidney disease and certain cancer patients receiving chemotherapy. The drugs have been successful at helping patients avoid blood transfusions, which are necessary to boost red-blood cell levels that fall too low. The products fall into a class of drugs known as erythropoiesis-stimulating agents, or ESAs.
Bennett said more research is needed to look at the drugs' impact on tumors, noting that some studies have shown faster tumor growth, in order to figure out which patients should or shouldn't receive treatment with the drugs. Other research has suggested that the same mechanism the drugs use to boost red-blood cell counts could also fuel tumor growth.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; jennifer.corbett@dowjones.com
(END) Dow Jones Newswires
02-26-081615ET
Copyright (c) 2008 Dow Jones & Company, Inc.
schöner Artikel zu JNJ:
Johnson & Johnson: Doubling Its Dividend Every 5 Years
http://seekingalpha.com/article/65466-johnson-johnson-doubli…
Johnson & Johnson: Doubling Its Dividend Every 5 Years
http://seekingalpha.com/article/65466-johnson-johnson-doubli…
Trading Spotlight
interessant:
Johnson & Johnson Pharmaceutical Pipeline Review
posted on: February 18, 2008 | about stocks: JNJ
Print Email
Dow component Johnson & Johnson Inc. (NYSE: JNJ) recently reported 4Q07 earnings of $0.88 and FY07 EPS of $4.15, a 10% increase from 2006 and $0.02 above analysts estimates (see conference call transcript). I will take this time to provide you with an overview of the company's pharmaceutical portfolio and its outlook for FY08.
In 2007, pharmaceutical sales increased 4% overall (6% ex-US).
Existing Drugs
1) Topamax - Strong 2007 performer, approval for epilepsy treatment in 2007, boost from usage as migraine prevention, mostly US, generic competition in 2009?
2) Levaquin - Strong 2007 performer, growth in international sales buoyed 2007 revenues, increased competition in the US
3) Risperdal (Consta and Invega) - Strong 2007 performer, but older version hurt by generic competition in international markets, patent being challenged by generics in US.
4) Remicade - Strong 2007 performer, increased competition
from other biologics, strong international growth
5) Aciphex - Strong 2007 performer, patent being challenged by generics
6) Concerta - Strong 2007 performer, possible generic in the wings as JNJ asks FDA for clinical trials
7) Velcade - Strong 2007 performer, pending EU approval for use on multiple myeloma
8) Eprex/Procrit - 12% decline in revenue, safety concerns, competition (Amgen/Aranesp), competition in Europe (Roche/Mircera), Medicare restrictions
9) Duragesic - generic competition started in 2007
10) Ultracet - generic competition started in 2007
11) Sporanox - generic competition started in 2007
12) Ortho Tri-Cyclen - huge competition for oral contraceptives, patent being challenged by generics
13) Razadyne - patent being challenged by generics
Drug Pipeline
1) Doribax - approved in October 2007 for UTIs, pending for pneumonia, and on all accounts in EU
2) Intelence - HIV/AIDS drug approved this month
3) A schizophrenia drug coming online possible Fall 2008
4) Depoxetene in Europe for premature ejaculation, possible 2008 market date
5) Cefpobritole for complicated skin infections and pneumonia, possible 2008 market date
6) A drug for plaque psoriasis, possible 2008 market date
7) Tapentadol filing for approval in 2008
8) Rivaroxaban for knee and hip replacement patients filing in 2008
9) A drug to treat RA , filing for approval in 2008
10) Telaprevir for hep C, filing for approval in 2010
11) An oral factor Xa inhibitor strong Phase III results
Feel free to post updates or corrections.
Johnson & Johnson Pharmaceutical Pipeline Review
posted on: February 18, 2008 | about stocks: JNJ
Print Email
Dow component Johnson & Johnson Inc. (NYSE: JNJ) recently reported 4Q07 earnings of $0.88 and FY07 EPS of $4.15, a 10% increase from 2006 and $0.02 above analysts estimates (see conference call transcript). I will take this time to provide you with an overview of the company's pharmaceutical portfolio and its outlook for FY08.
In 2007, pharmaceutical sales increased 4% overall (6% ex-US).
Existing Drugs
1) Topamax - Strong 2007 performer, approval for epilepsy treatment in 2007, boost from usage as migraine prevention, mostly US, generic competition in 2009?
2) Levaquin - Strong 2007 performer, growth in international sales buoyed 2007 revenues, increased competition in the US
3) Risperdal (Consta and Invega) - Strong 2007 performer, but older version hurt by generic competition in international markets, patent being challenged by generics in US.
4) Remicade - Strong 2007 performer, increased competition
from other biologics, strong international growth
5) Aciphex - Strong 2007 performer, patent being challenged by generics
6) Concerta - Strong 2007 performer, possible generic in the wings as JNJ asks FDA for clinical trials
7) Velcade - Strong 2007 performer, pending EU approval for use on multiple myeloma
8) Eprex/Procrit - 12% decline in revenue, safety concerns, competition (Amgen/Aranesp), competition in Europe (Roche/Mircera), Medicare restrictions
9) Duragesic - generic competition started in 2007
10) Ultracet - generic competition started in 2007
11) Sporanox - generic competition started in 2007
12) Ortho Tri-Cyclen - huge competition for oral contraceptives, patent being challenged by generics
13) Razadyne - patent being challenged by generics
Drug Pipeline
1) Doribax - approved in October 2007 for UTIs, pending for pneumonia, and on all accounts in EU
2) Intelence - HIV/AIDS drug approved this month
3) A schizophrenia drug coming online possible Fall 2008
4) Depoxetene in Europe for premature ejaculation, possible 2008 market date
5) Cefpobritole for complicated skin infections and pneumonia, possible 2008 market date
6) A drug for plaque psoriasis, possible 2008 market date
7) Tapentadol filing for approval in 2008
8) Rivaroxaban for knee and hip replacement patients filing in 2008
9) A drug to treat RA , filing for approval in 2008
10) Telaprevir for hep C, filing for approval in 2010
11) An oral factor Xa inhibitor strong Phase III results
Feel free to post updates or corrections.
04.02.2008 14:22
FDA to review J&J psoriasis drug
Private Equity boomt!
16% p.a. seit 50 Jahren! 7% Sofortrente! Hohe Renditen bei breiter Risikostreuung!
Top Steuersparmodell
Steuern sparen mit Denkmal Immobilien: Bis zu 90% des Kaufpreises abschreibbar!
Welcher Typ sind Sie?
Für jeden Anlage-Typ das passende Produkt von AKZENT Invest. Machen auch Sie mehr aus Ihrem Geld.
HORSHAM, Pa. (AP) - Johnson&Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.
Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch and bleed.
Centocor discovered ustekinumab and holds exclusive marketing rights to the product in the United States. Janssen-Cilag International NV has exclusive marketing rights in countries outside of the United States.
Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
FDA to review J&J psoriasis drug
Private Equity boomt!
16% p.a. seit 50 Jahren! 7% Sofortrente! Hohe Renditen bei breiter Risikostreuung!
Top Steuersparmodell
Steuern sparen mit Denkmal Immobilien: Bis zu 90% des Kaufpreises abschreibbar!
Welcher Typ sind Sie?
Für jeden Anlage-Typ das passende Produkt von AKZENT Invest. Machen auch Sie mehr aus Ihrem Geld.
HORSHAM, Pa. (AP) - Johnson&Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.
Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch and bleed.
Centocor discovered ustekinumab and holds exclusive marketing rights to the product in the United States. Janssen-Cilag International NV has exclusive marketing rights in countries outside of the United States.
Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
der Vollständigkeite halber:
J&J 4Q Profit Rises; Revenue Climbs
By LINDA A. JOHNSON
Font Scale:
Posted 22 January 2008 @ 01:07 pm EST
* IBTimes RSS
* Print
* E-Mail
* digg
* Del.icio.us
TRENTON, N.J. (AP) - Health care products maker Johnson & Johnson's profit rose almost 10 percent in the fourth quarter as revenues jumped by double digits despite sales drops for two key product lines.
Article Tags
4q climbs profit revenue rises
* Merrill Takes $11.5 Bln Write-Down
* IBM's Strong 4Q Results Boost Tech Sector
* Bank of America 4Q Profit Plunges
More News Related to 4q >>
* Meredith 2Q Profit Climbs on Publishing
* Dollar Climbs Against Euro
* Ark. Unemployment Rate Climbs
More News Related to climbs >>
* Coca-Cola Enterprises boosts 2007 profit estimate
* Cisco Eanings Jump, Shares Slide on Outlook
* Expedia third-quarter profit gains on bookings
More News Related to profit >>
* GE Profit Meets Expectations
* Wesfarmers-Coles combined revenue seen at $39 bln
More News Related to revenue >>
* Oil rises on weaker dollar, OPEC
* Frontier Airlines traffic rises 22Pct.
* Berkshire Profit Rises 64pct
More News Related to rises >>
The New Brunswick, N.J.-based maker of prescription drugs, medical devices, contact lenses and baby care items on Tuesday reported net income of $2.37 billion, or 82 cents per share, up from $2.17 billion, or 74 cents per share, a year earlier. Excluding one-time items, net income would have been 88 cents per share.
Revenues totaled $15.96 billion, up 16.6 percent from $13.7 billion in the year-ago quarter. Most growth came overseas, with international sales jumping 26 percent and currency exchange rates boosting revenues nearly 5 percent.
"This is as good as it gets for them, and it is not a harbinger for good times in the future," said analyst Steve Brozak of WBB Securities.
Analysts surveyed by Thomson Financial were expecting earnings of 86 cents per share excluding one-time items on revenues of $15.4 billion.
"In 2007, we delivered strong results across our broad base of businesses and exceeded expectations," Chief Executive Officer Bill Weldon told analysts at a meeting. "We achieved those results despite having to work through one of the more difficult years in Johnson & Johnson's history."
Last July, the company announced its biggest restructuring ever, saying it would cut up to 4 percent of jobs due to looming patent expirations for key drugs and continuing sales declines for two top products. Anemia treatment Procrit J&J's No. 1 drug until 2005 saw sales fall 20 percent to $628 million in the fourth quarter. In the same quarter, sales fell nearly one-third to $415 million for Cypher, a metal-mesh tube, or stent, that slowly releases medicine to keep a heart artery open after a blockage is cleared.
Brozak said he expects Procrit sales to continue to fall and doesn't see "the stent business getting better."
In the fourth quarter, sales for J&J's medical devices and diagnostics business rose 11 percent, to $5.8 billion, while prescription drug sales rose 7.5 percent to $6.4 billion. Sales of consumer health products such skin and dental products and nonprescription medicines hit $3.8 billion, up 48 percent, mainly due to the December 2006 acquisition of Pfizer Inc.'s consumer health business.
J&J said it expects earnings per share for 2008 to total $4.39 to $4.44, excluding one-time items. Analysts have been looking for earnings of $4.42 a share for 2008.
J&J 4Q Profit Rises; Revenue Climbs
By LINDA A. JOHNSON
Font Scale:
Posted 22 January 2008 @ 01:07 pm EST
* IBTimes RSS
* digg
* Del.icio.us
TRENTON, N.J. (AP) - Health care products maker Johnson & Johnson's profit rose almost 10 percent in the fourth quarter as revenues jumped by double digits despite sales drops for two key product lines.
Article Tags
4q climbs profit revenue rises
* Merrill Takes $11.5 Bln Write-Down
* IBM's Strong 4Q Results Boost Tech Sector
* Bank of America 4Q Profit Plunges
More News Related to 4q >>
* Meredith 2Q Profit Climbs on Publishing
* Dollar Climbs Against Euro
* Ark. Unemployment Rate Climbs
More News Related to climbs >>
* Coca-Cola Enterprises boosts 2007 profit estimate
* Cisco Eanings Jump, Shares Slide on Outlook
* Expedia third-quarter profit gains on bookings
More News Related to profit >>
* GE Profit Meets Expectations
* Wesfarmers-Coles combined revenue seen at $39 bln
More News Related to revenue >>
* Oil rises on weaker dollar, OPEC
* Frontier Airlines traffic rises 22Pct.
* Berkshire Profit Rises 64pct
More News Related to rises >>
The New Brunswick, N.J.-based maker of prescription drugs, medical devices, contact lenses and baby care items on Tuesday reported net income of $2.37 billion, or 82 cents per share, up from $2.17 billion, or 74 cents per share, a year earlier. Excluding one-time items, net income would have been 88 cents per share.
Revenues totaled $15.96 billion, up 16.6 percent from $13.7 billion in the year-ago quarter. Most growth came overseas, with international sales jumping 26 percent and currency exchange rates boosting revenues nearly 5 percent.
"This is as good as it gets for them, and it is not a harbinger for good times in the future," said analyst Steve Brozak of WBB Securities.
Analysts surveyed by Thomson Financial were expecting earnings of 86 cents per share excluding one-time items on revenues of $15.4 billion.
"In 2007, we delivered strong results across our broad base of businesses and exceeded expectations," Chief Executive Officer Bill Weldon told analysts at a meeting. "We achieved those results despite having to work through one of the more difficult years in Johnson & Johnson's history."
Last July, the company announced its biggest restructuring ever, saying it would cut up to 4 percent of jobs due to looming patent expirations for key drugs and continuing sales declines for two top products. Anemia treatment Procrit J&J's No. 1 drug until 2005 saw sales fall 20 percent to $628 million in the fourth quarter. In the same quarter, sales fell nearly one-third to $415 million for Cypher, a metal-mesh tube, or stent, that slowly releases medicine to keep a heart artery open after a blockage is cleared.
Brozak said he expects Procrit sales to continue to fall and doesn't see "the stent business getting better."
In the fourth quarter, sales for J&J's medical devices and diagnostics business rose 11 percent, to $5.8 billion, while prescription drug sales rose 7.5 percent to $6.4 billion. Sales of consumer health products such skin and dental products and nonprescription medicines hit $3.8 billion, up 48 percent, mainly due to the December 2006 acquisition of Pfizer Inc.'s consumer health business.
J&J said it expects earnings per share for 2008 to total $4.39 to $4.44, excluding one-time items. Analysts have been looking for earnings of $4.42 a share for 2008.
20.01.2008 22:37
Johnson & Johnson says unit's HIV drug granted FDA accelerated approval
LONDON (Thomson Financial) - Johnson&Johnson (News/Aktienkurs) said the US Food and Drug has granted accelerated approval to the anti-HIV medication Intelence tablets, developed by Johnson&Johnson unit Tibotec, a division of Ortho Biotech Products LP.
The drug is used as part of HIV combination therapy, Johnson&Johnson said.
FDA accelerated approval procedures allow for earlier approval of drugs
that provide a meaningful therapeutic benefit over existing treatment for
serious or life-threatening diseases.
tf.TFN-Europe_newsdesk@thomson.com
vs
Johnson & Johnson says unit's HIV drug granted FDA accelerated approval
LONDON (Thomson Financial) - Johnson&Johnson (News/Aktienkurs) said the US Food and Drug has granted accelerated approval to the anti-HIV medication Intelence tablets, developed by Johnson&Johnson unit Tibotec, a division of Ortho Biotech Products LP.
The drug is used as part of HIV combination therapy, Johnson&Johnson said.
FDA accelerated approval procedures allow for earlier approval of drugs
that provide a meaningful therapeutic benefit over existing treatment for
serious or life-threatening diseases.
tf.TFN-Europe_newsdesk@thomson.com
vs
10.01.2008 19:37
FDA sets February meeting for J&J drug
WASHINGTON (AP) - Government advisers will meet in late February to review Johnson&Johnson's antibiotic to treat skin infections.
The Food and Drug Administration's panel of outside antibiotic experts will consider approval of the company's ceftobiprole at a Feb. 28 meeting, according to a notice posted to the agency's Web site. The FDA is not required to follow the panel's recommendations, though it often does.
Shares of Johnson&Johnson (News/Aktienkurs) were flat at $67.8o in afternoon trading.
Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
FDA sets February meeting for J&J drug
WASHINGTON (AP) - Government advisers will meet in late February to review Johnson&Johnson's antibiotic to treat skin infections.
The Food and Drug Administration's panel of outside antibiotic experts will consider approval of the company's ceftobiprole at a Feb. 28 meeting, according to a notice posted to the agency's Web site. The FDA is not required to follow the panel's recommendations, though it often does.
Shares of Johnson&Johnson (News/Aktienkurs) were flat at $67.8o in afternoon trading.
Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Durchsuchen
17:50 Uhr · wO Newsflash · Apple |
07.05.24 · wO Newsflash · Carl Zeiss Meditec |
06.05.24 · wO Newsflash · Amgen |
05.05.24 · wallstreetONLINE Redaktion · Allianz |
05.05.24 · Aktienwelt360 · Johnson & Johnson |
03.05.24 · wO Newsflash · Amgen |
01.05.24 · dpa-AFX · Amazon |
01.05.24 · dpa-AFX · Amazon |